Intersect ENT Stock Forecast, Price & News

-0.04 (-0.15 %)
(As of 09/16/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume204,139 shs
Average Volume414,906 shs
Market Capitalization$910.17 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive XENT News and Ratings via Email

Sign-up to receive the latest news and ratings for Intersect ENT and its competitors with MarketBeat's FREE daily newsletter.

Intersect ENT logo

About Intersect ENT

Intersect ENT, Inc. is a commercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. Its products include PROPEL and SINUVA. The PROPEL used to maintain the opening and locally deliver steroid after sinus surgery. The SINUVA is used to treat adult patients with ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps. The company was founded by Donald J. Eaton in October 2003 and is headquartered in Menlo Park, CA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.59 out of 5 stars

Medical Sector

993rd out of 1,352 stocks

Surgical & Medical Instruments Industry

102nd out of 123 stocks

Analyst Opinion: 1.0Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Intersect ENT (NASDAQ:XENT) Frequently Asked Questions

Is Intersect ENT a buy right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intersect ENT in the last year. There are currently 6 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Intersect ENT stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in XENT, but not buy additional shares or sell existing shares.
View analyst ratings for Intersect ENT
or view top-rated stocks.

What stocks does MarketBeat like better than Intersect ENT?

Wall Street analysts have given Intersect ENT a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Intersect ENT wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Intersect ENT?

Intersect ENT saw a drop in short interest during the month of August. As of August 13th, there was short interest totaling 1,360,000 shares, a drop of 35.2% from the July 29th total of 2,100,000 shares. Based on an average daily volume of 743,000 shares, the days-to-cover ratio is currently 1.8 days. Currently, 4.3% of the shares of the company are sold short.
View Intersect ENT's Short Interest

When is Intersect ENT's next earnings date?

Intersect ENT is scheduled to release its next quarterly earnings announcement on Monday, November 1st 2021.
View our earnings forecast for Intersect ENT

How were Intersect ENT's earnings last quarter?

Intersect ENT, Inc. (NASDAQ:XENT) announced its quarterly earnings data on Friday, August, 6th. The medical equipment provider reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by $0.07. The medical equipment provider had revenue of $27.30 million for the quarter, compared to analyst estimates of $27.77 million. Intersect ENT had a negative trailing twelve-month return on equity of 102.23% and a negative net margin of 66.55%. The company's quarterly revenue was up 178.6% on a year-over-year basis. During the same period in the previous year, the business posted ($0.65) EPS.
View Intersect ENT's earnings history

How has Intersect ENT's stock been impacted by COVID-19 (Coronavirus)?

Intersect ENT's stock was trading at $21.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, XENT stock has increased by 27.1% and is now trading at $27.32.
View which stocks have been most impacted by COVID-19

What guidance has Intersect ENT issued on next quarter's earnings?

Intersect ENT issued an update on its FY 2021 earnings guidance on Thursday, August, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $117 million-$121 million, compared to the consensus revenue estimate of $119.79 million.

What price target have analysts set for XENT?

6 Wall Street analysts have issued 12 month price objectives for Intersect ENT's stock. Their forecasts range from $19.00 to $32.00. On average, they expect Intersect ENT's share price to reach $26.47 in the next year. This suggests that the stock has a possible downside of 3.1%.
View analysts' price targets for Intersect ENT
or view top-rated stocks among Wall Street analysts.

Who are Intersect ENT's key executives?

Intersect ENT's management team includes the following people:
  • Thomas A. West, President, Chief Executive Officer & Director
  • Randy Meier, Chief Financial Officer & Executive Vice President
  • Patrick A. Broderick, Secretary, Executive VP & General Counsel
  • Mark L. Alley, Vice President-Sales
  • Reyna M. Fernandez, Chief Human Resource Officer

What is Thomas West's approval rating as Intersect ENT's CEO?

7 employees have rated Intersect ENT CEO Thomas West on Thomas West has an approval rating of 41% among Intersect ENT's employees. This puts Thomas West in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Intersect ENT's key competitors?

What other stocks do shareholders of Intersect ENT own?

What is Intersect ENT's stock symbol?

Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."

Who are Intersect ENT's major shareholders?

Intersect ENT's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Artisan Partners Limited Partnership (13.43%), FMR LLC (10.45%), BlackRock Inc. (8.87%), First Light Asset Management LLC (6.64%), Vanguard Group Inc. (5.22%) and State Street Corp (3.02%). Company insiders that own Intersect ENT stock include Richard A Meier, Robert H Binney, Jr and Thomas A West.
View institutional ownership trends for Intersect ENT

Which major investors are selling Intersect ENT stock?

XENT stock was sold by a variety of institutional investors in the last quarter, including Great Point Partners LLC, JPMorgan Chase & Co., California Public Employees Retirement System, Goldman Sachs Group Inc., Russell Investments Group Ltd., Nuveen Asset Management LLC, Wells Fargo & Company MN, and Neuberger Berman Group LLC.
View insider buying and selling activity for Intersect ENT
or view top insider-selling stocks.

Which major investors are buying Intersect ENT stock?

XENT stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, Artisan Partners Limited Partnership, First Light Asset Management LLC, Millennium Management LLC, State Street Corp, Sei Investments Co., Grandeur Peak Global Advisors LLC, and Altium Capital Management LP. Company insiders that have bought Intersect ENT stock in the last two years include Richard A Meier, and Thomas A West.
View insider buying and selling activity for Intersect ENT
or or view top insider-buying stocks.

How do I buy shares of Intersect ENT?

Shares of XENT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intersect ENT's stock price today?

One share of XENT stock can currently be purchased for approximately $27.32.

How much money does Intersect ENT make?

Intersect ENT has a market capitalization of $910.17 million and generates $80.55 million in revenue each year. The medical equipment provider earns $-72,320,000.00 in net income (profit) each year or ($2.05) on an earnings per share basis.

How many employees does Intersect ENT have?

Intersect ENT employs 406 workers across the globe.

What is Intersect ENT's official website?

The official website for Intersect ENT is

Where are Intersect ENT's headquarters?

Intersect ENT is headquartered at 1555 ADAMS DRIVE, MENLO PARK CA, 94025.

How can I contact Intersect ENT?

Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The medical equipment provider can be reached via phone at (650) 641-2100 or via email at [email protected]

This page was last updated on 9/17/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.